LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), which is developing a testosterone gel (LibiGel®) for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, today commented on a paper published in the May 15, 2009 issue of AIDS, the Journal of the International AIDS Society, on the effect of testosterone in women infected with HIV. The peer-reviewed journal reported results of a randomized, placebo-controlled trial of testosterone in HIV-infected women indicating that long-term testosterone administration was well tolerated in HIV-infected women and resulted in significant improvement in body composition, bone mineral density (BMD), and quality of life indices.
